Exchange Traded Concepts LLC Grows Stock Position in Vor Biopharma Inc. (NYSE:VOR)

Exchange Traded Concepts LLC boosted its stake in shares of Vor Biopharma Inc. (NYSE:VOR) by 40.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 165,805 shares of the company’s stock after buying an additional 48,017 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Vor Biopharma were worth $116,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Vor Biopharma during the 2nd quarter valued at $53,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vor Biopharma in the 2nd quarter worth $63,000. Hsbc Holdings PLC grew its holdings in Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after buying an additional 31,333 shares in the last quarter. Renaissance Technologies LLC lifted its position in Vor Biopharma by 48.0% during the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after purchasing an additional 160,642 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after buying an additional 27,597 shares in the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Trading Up 4.8 %

NYSE:VOR opened at $0.71 on Wednesday. The company has a market cap of $48.52 million, a price-to-earnings ratio of -0.40 and a beta of -0.35. Vor Biopharma Inc. has a twelve month low of $0.63 and a twelve month high of $3.14. The stock has a fifty day simple moving average of $0.83 and a 200-day simple moving average of $1.17.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). As a group, equities research analysts predict that Vor Biopharma Inc. will post -1.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on VOR. HC Wainwright restated a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a research report on Friday, September 6th. JMP Securities restated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research report on Friday, September 6th. Finally, Barclays dropped their target price on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vor Biopharma currently has a consensus rating of “Buy” and an average price target of $10.92.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.